2. Search Result
Search Result
Results for "

CCDC6

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133551
    WF-47-JS03

    		RET Cancer
    WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration .
    WF-47-JS03
  • HY-112301
    Pralsetinib
    15+ Cited Publications

    BLU-667

    		 RET Cancer
    Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
    Pralsetinib
  • HY-RS20872
    Ccdc6 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ccdc6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccdc6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ccdc6 Mouse Pre-designed siRNA Set A
    Ccdc6 Mouse Pre-designed siRNA Set A
  • HY-RS27389
    Ccdc6 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ccdc6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccdc6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ccdc6 Rat Pre-designed siRNA Set A
    Ccdc6 Rat Pre-designed siRNA Set A
  • HY-RS02051
    CCDC6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCDC6 Human Pre-designed siRNA Set A contains three designed siRNAs for CCDC6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCDC6 Human Pre-designed siRNA Set A
    CCDC6 Human Pre-designed siRNA Set A
  • HY-170926
    CQ1373

    		RET Apoptosis Cancer
    CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research .
    CQ1373
  • HY-170809
    RET-IN-29

    		RET Cancer
    RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. RET-IN-29 exhibits inhibitory potency against the BaF3 cells harboring CCDC6-RET V804M mutation with an IC50 value of 0.715 μM. RET-IN-29 is promising for research of non-small cell lung cancer (NSCLC) .
    RET-IN-29
  • HY-144131
    RET-IN-11

    		Apoptosis RET Cancer
    RET-IN-11 is a potent and selective RET inhibitor with IC50s of 6.20 nM, 18.68 nM for RET and RET V804M, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell apoptosis .
    RET-IN-11
  • HY-112301R
    Pralsetinib (Standard)

    BLU-667 (Standard)

    		 Reference Standards RET Cancer
    Pralsetinib (Standard) is the analytical standard of Pralsetinib. This product is intended for research and analytical applications. Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
    Pralsetinib (Standard)
  • HY-178061
    APS03118

    		ERK RET Cancer
    APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
    APS03118
  • HY-153676
    RET-IN-23

    		RET Cancer
    RET-IN-23 (compound 17) is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. RET-IN-23 shows anti-tumor activity .
    RET-IN-23
  • HY-146710
    RET-IN-16

    		RET Cancer
    RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
    RET-IN-16

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: